Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting
Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo (TM) MicroShunt implant (MicroShunt) with a simultaneous Ologen (TM) implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repositorio: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p17839 |
| Acceso en línea: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17839 http://ddd.uab.cat/record/305621 |
| Access Level: | acceso abierto |
| Palabra clave: | Glaucoma glaucoma surgery intraocular pressure MIGS Ologen Preserflo MicroShunt |
| id |
ES_ad4e270c8ffb92913279b3ce4de5a81c |
|---|---|
| oai_identifier_str |
oai:iibsantpau.fundanetsuite.com:p17839 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical settingRojo-Arnao, MMartinez-de-la-Casa, JMAlbis-Donado, OYañez-Castro, GMaroto-Cejudo, RTellez, JMenoyo-Calatayud, RGlaucomaglaucoma surgeryintraocular pressureMIGSOlogenPreserflo MicroShuntPurpose: This study aims to assess the effectiveness and safety of combining the Preserflo (TM) MicroShunt implant (MicroShunt) with a simultaneous Ologen (TM) implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 +/- 5.8 mmHg to 11.4 +/- 2.6 mmHg at 18 months ( P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 +/- 5.2 mmHg to 11.7 +/- 2.5 mmHg ( P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 +/- 5.8 mmHg to 10.9 +/- 2.7 mmHg ( P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 +/- 1.1 to 0.3 +/- 0.7 in the overall study population ( P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen (TM) and Preserflo (TM) MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.WOLTERS KLUWER MEDKNOW PUBLICATIONS2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17839http://ddd.uab.cat/record/305621INDIAN JOURNAL OF OPHTHALMOLOGYISSN: 03014738ISSNe: 19983689reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p178392026-06-14T12:41:47Z |
| dc.title.none.fl_str_mv |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| title |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| spellingShingle |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting Rojo-Arnao, M Glaucoma glaucoma surgery intraocular pressure MIGS Ologen Preserflo MicroShunt |
| title_short |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| title_full |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| title_fullStr |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| title_full_unstemmed |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| title_sort |
Preserflo™ MicroShunt implantation combined with Ologen™ in primary and secondary glaucoma patients in a clinical setting |
| dc.creator.none.fl_str_mv |
Rojo-Arnao, M Martinez-de-la-Casa, JM Albis-Donado, O Yañez-Castro, G Maroto-Cejudo, R Tellez, J Menoyo-Calatayud, R |
| author |
Rojo-Arnao, M |
| author_facet |
Rojo-Arnao, M Martinez-de-la-Casa, JM Albis-Donado, O Yañez-Castro, G Maroto-Cejudo, R Tellez, J Menoyo-Calatayud, R |
| author_role |
author |
| author2 |
Martinez-de-la-Casa, JM Albis-Donado, O Yañez-Castro, G Maroto-Cejudo, R Tellez, J Menoyo-Calatayud, R |
| author2_role |
author author author author author author |
| dc.subject.none.fl_str_mv |
Glaucoma glaucoma surgery intraocular pressure MIGS Ologen Preserflo MicroShunt |
| topic |
Glaucoma glaucoma surgery intraocular pressure MIGS Ologen Preserflo MicroShunt |
| description |
Purpose: This study aims to assess the effectiveness and safety of combining the Preserflo (TM) MicroShunt implant (MicroShunt) with a simultaneous Ologen (TM) implant in patients with glaucoma. Methods: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. Results: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 +/- 5.8 mmHg to 11.4 +/- 2.6 mmHg at 18 months ( P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 +/- 5.2 mmHg to 11.7 +/- 2.5 mmHg ( P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 +/- 5.8 mmHg to 10.9 +/- 2.7 mmHg ( P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 +/- 1.1 to 0.3 +/- 0.7 in the overall study population ( P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. Conclusion: The combination of Ologen (TM) and Preserflo (TM) MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17839 http://ddd.uab.cat/record/305621 |
| url |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17839 http://ddd.uab.cat/record/305621 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
WOLTERS KLUWER MEDKNOW PUBLICATIONS |
| publisher.none.fl_str_mv |
WOLTERS KLUWER MEDKNOW PUBLICATIONS |
| dc.source.none.fl_str_mv |
INDIAN JOURNAL OF OPHTHALMOLOGY ISSN: 03014738 ISSNe: 19983689 reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| instname_str |
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| reponame_str |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| collection |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869416428132630528 |
| score |
15,812429 |